Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression

Iman Osman, Maryann Mikhail, Brian Shuch, Megan Clute, Carol D. Cheli, Farooq Ghani, Robert P. Thiel, Samir S. Taneja

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


Purpose: We determined the association between serum levels of shed Her-2/neu protein and disease progression in men with prostate cancer. Materials and Methods: Serum from 279 patients enrolled in a prospective serum bank and database at New York University Medical Center was analyzed using the Food and Drug Administration approved Immuno-1™ Her-2/neu assay. Patients were classified by the Prostate-Specific Antigen Working Group model into 5 groups, namely group 1-no evidence of cancer in 60, group 2-clinically localized disease in 67, group 3-prostate specific antigen increasing after therapy and no clinical metastases in 77, group 4-clinical metastases and castration sensitivity in 42, and group 5-clinical metastases and castration resistance in 33. A cutoff of 14 ng/ml for normal serum Her-2/neu was established based on the 95th order statistic in group 1. Results: Of 279 patients 37 (13.3%) had increased serum Her-2/neu, that is 5%, 11.9%, 10.4%, 16.7% and 33.3% in groups 1 to 5, respectively. There was a significant difference between patients with (groups 4 and 5) and without (groups 2 and 3) clinical metastases (p = 0.006). In group 5 patients serum Her-2/neu was significantly higher than in group 2 patients (p <0.02). The risk of cause specific death increased significantly with each unit increase in serum Her-2/neu (p <0.001). Conclusions: Increased serum Her-2/neu correlates with the presence of metastatic disease and it may indicate an increased risk of death in patients with castrate, metastatic prostate cancer. The detection of serum Her-2/neu is a minimally invasive alternative to tumor sampling for identifying potential candidates for anti-Her-2/neu treatment strategies. Further studies are needed to optimize this assay for application in the clinical setting.

Original languageEnglish
Pages (from-to)2174-2177
Number of pages4
JournalJournal of Urology
Issue number6
Publication statusPublished - Dec 2005


  • Epidermal growth factor
  • Prostate
  • Prostatic neoplasms
  • Receptor
  • Serum


Dive into the research topics of 'Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression'. Together they form a unique fingerprint.

Cite this